Form 4: Cogent Biosciences Executive Cole Pinnow Granted Stock Options

Cole Pinnow, Chief Commercial Officer of Cogent Biosciences, was granted stock options for 240,000 shares on January 23, 2025, vesting monthly over four years.

Summary

• Cole Pinnow, the Chief Commercial Officer of Cogent Biosciences, received stock options on January 23, 2025.
• The options grant covers 240,000 shares of Cogent Biosciences common stock.
• The exercise price of the options is $8.89 per share.
• The options vest in equal monthly installments over a four-year period.
• The options expire on January 23, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management with shareholder interests.

Positives

• The grant of stock options to the Chief Commercial Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value. Companies like Amgen, Gilead, and Biogen also use stock options as part of their compensation packages.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen use similar equity-based compensation to incentivize their executives.
• The vesting schedule of four years is also typical for these types of grants.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the Chief Commercial Officer to drive sales and market share, benefiting the company and its stakeholders.

Key Dates